COST-Bl Working Party on Population Approaches: L.Aarons(1), L.P.Balant(2), F.Mentre(3), P.L.Morselli(4), M.Rowland(1), J.-L.Steimer(5), and S.Vozeh(6)
Population Approaches in Drug Development: Report on an expert meeting to discuss population pharmacokinetic/pharmacodynamic software
|
Athanassios Iliadis
APIS : A software for clinical and experimental pharmacokinetics
|
Saik Urien
MicroPharm Population (MP2) - An interactive and user-friendly interfaced program for population pharmacokinetics.
|
Xavier Barbaut (1,2), Roger W. Jelliffe (2), Pascal Maire (1,2), Alan Schumitzky (2), Michael van Guilder (2), Bruno Charpiat (1)
NPEM2: A Nonparametric Program Useful For Clinical Uses : Both Population Pharmacokinetic Modeling, Leading To “Multiple Model” (MM) Adaptive Control
|
R.Gomeni
P-PHARM: A Population Pharmacokinetic-Pharmacodynamic Data Modeling Software
|
Jon Wakefield
POPKAN - Population Pharmacokinetic Analysis using Bayesian Inference
|
Y. Merlé, F. Mentré, J. Gilles and A. Mallet.
The Nonparametric Maximum Likelihood Method (NPML)
|
Mats O. Karlsson
Stability Of Covariate Models
|
L. Claret, A. Iliadis.
Non-Parametric Density Estimation Applied To Population Studies
|
0. Petricoul(1,2), A. Iliadis(1), L. Claret(1). C. Puozzo(2)
Information Theory in Drug Development. Applications to a new antidepressant.
|
B.Charpiat(1), N.Laurent(1), J.M.Sab(2), V.Breant(1), C.Ducerf(3), S.Tigaud(4), D.Robert(2), R.W.Jelliffe(5)
Cyclosporine Population Pharmacokinetic Parameters In The Early Postoperative Hepatic Transplantation Phase: Preliminary Results
|
James Bennett and Jon Wakefield
Covariate Identification for Population Pharmacokinetic Modelling
|
S. Walker, J.C. Wakefield
Population analysis of a dose ranging study
|
E.M. Parker, M. Hutchison
Pharmacokinetics of Meropenem in pediatrics - NONMEM analysis
|
P Burtin (1,3), E Jacqz-Aigrain (1), P Girard (2)
Population pharmacokinetics of midazolam in neonates
|
Dinesh de Alwis(1), Leon Aarons(1) and Jonathan Palmer(2)
The Population Pharmacokinetics of Ondansetron from Phase 1 Studies
|
A.C.Falcao(1,2), M.M.Fernandez de Gatta, M.F.Delgado Iribarnegaray, D.Santos Buelga, M.J.Garcia, A.Dominguez-Gil, J.M.Lanao
Caffeine Pharmacokinetics In a Pediatric Population
|
C. Laveille Pharm.D., M. Malbezin M.D, D. Guez M.D., R. Jochemsen Ph.D.
Pharmacokinetics Of S-12024 By A Prospective Population Approach In Phase II.
|
Valérie Cosson, Pharm D(1), Pr Jean-Michel Scherrmann(2), ElianeFuseau,PhD(1)
Population Pharmacokinetics Of Oral Sumatriptan
|
S.F. Marshall, H.L. Elliott, P.A. Meredith.
A Population Approach to Dose Versus Response Relationship For Simvastatin in Hypertensive Hypercholesterolaemic Patients.
|
Lacey LF(1), Kler L.(2)
Effect of covariatcs on steady-state trough plasma bismuth concentrations from GR122311X in duodenal ulcer patients.
|
M. Tod, C. Pobel, O. Petitjean, N. Brion, J. Garcia-Mace
A Population Pharmacokinetic Study Of Alminoprofen Penetration Into Synovial Fluid
|
M.Tod, J.M. Rocchisani
Optimal Sampling Times Determination By Criteria Incorporating Knowledge Of Parameter Distribution In The Population
|
Niclas Jonsson, Janet R. Wade and Mats O. Karlsson
Comparison of Practical Sampling Strategies for Population Pharmacokinetic Studies
|
Lynne Evans, Leon Aarons
Use of the EM algorithm in population pharmacokinetic analysis
|
M.T. Mateu; J.J. Perez-Ruixo; V.G. Casabo; N.V. Jimenez
Estimation of Population Pharmacokinetic Parameters of Tobramycin in Intensive Care Unit Patients Using Different Programs
|
D. Breilh, C. Pobel, L. Lagagnier, P. Maire, M.C. Saux
Evaluation Of Bayesian Estimators For Adaptative Control Of Vancomycin Built With Two Methods Of Population Modeling
|
Markus Jerling(1) , Yann Merlé(2) , France Mentré(2) and Alain Mallet(2)
Population pharmacokinetics of nortriptyline at monotherapy and during concomitant treatment with drugs that inhibit CYP2D6; an evaluation with the nonparametric maximum likelihood method
|
Carl Peck, Tom Ludden
Pitfalls in Retrospective Analysis in Search of Concentration-Effect Relationships
|
Mats O. Karlsson(1,3), Stuart L. Beal(2) and Lewis B. Sheiner(1,2)
Three New Residual Error Models For Population PK/PD Analyses
|
J.R. Wade, PhD(1,2), S.L. Beal PhD(2) and N.C. Sambol, PharmD(2)
Interaction between structural, statistical and covariate models in population pharmacokinetic analysis
|
Jaap W Mandema(1), Davide Verotta(2), and Lewis B Sheiner(2,3)
Diagnostics For Nonlinear Mixed Effects Models
|
Y. Merlé and F. Mentré
Comparison of Bayesian Optimal Designs with Respect to Variations of the Population Characteristics. For a Pharmacokinetic and a Pharmacodynamic Model
|
Constantin Efthymiopoulos, PhD, Valérie Cosson, Pharm D, Alan Bye, PhD
The Use of NONMEM in Interspecies Allometric Scaling
|
Alan V. Boddy, Michael Cole, Peng Bin, Andrew D.J. Pearson and David R. Newell
A limited sampling model with Bayesian estimation to determine carboplatin pharmacokinetics in paediatrics
|
E Chatelut(1,2), V Brunner(1), C Chevreau(1), A Pujol(1), H Roché(1), V Paschel(1), G Houin(2), R Bugat(1,2), P Canal(1)
Carboplatin Population Pharmacokinetics
|
Dr Alan Bye, Head of Clinical Pharmacokinetics Department
Issues and Suggested Solutions in Drug Development
|
René Bruno, N. Vivier, J.C. Vergniol, G. Montay and L.B. Sheiner(1)
A Validation For A Population Pharmacokinetic Model For Docetaxel
|
Andrew P. Grieve
Combining Studies : Opportunities And Pitfalls
|
Jean-Louis Steimer, Marie-Eve Ebelin
Implementation of pharmacometric approaches into clinical drug development ? A prospective view
|
Lewis B. Sheiner, MD
The Future Place Of Modeling In Drug Development
|
Jon Wakefield
Review of methods
|
